Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Promoter activity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Promoter activity. Displaying page 1 of 1.
    EudraCT Number: 2008-006871-60 Sponsor Protocol Number: DIRECTOR Start Date*: 2009-06-23
    Sponsor Name:University Hospital Heidelberg, Ruprechts-Karl-University Heidelberg
    Full Title: Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma
    Medical condition: progressive or recurrent glioblastoma after first surgery for glioblastoma and after completion of radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001690-16 Sponsor Protocol Number: BORTEM-17 Start Date*: 2018-05-29
    Sponsor Name:Helse Bergen HF
    Full Title: Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to Temozolomide phase 1B/II study
    Medical condition: recurrent or progressed WHO grade IV intracranial glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002325-18 Sponsor Protocol Number: CATARTIC Start Date*: 2021-09-28
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsatellite stable locally Advanced RecTal Cancer: the CATARTI...
    Medical condition: Localy advanced low-risk rectal cancer, placed at less then 15 cm form the anal verge and staged as cT = 2 and cN0 or cT1-3 cN1 (TNM classification 8th edition), without evidence of distant metasta...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10010023 Colorectal neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003338-17 Sponsor Protocol Number: TEMECT Start Date*: 2012-10-29
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)
    Full Title: Phase II study of temozolomide in metastatic colorectal cancer patients resistant to standard therapies and with O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation
    Medical condition: patients with metastatic colorectal cancer resistant to standard therapies and with O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000281-21 Sponsor Protocol Number: H6Q-MC-S039 Start Date*: 2007-09-05
    Sponsor Name:Eli Lilly and Company
    Full Title: Enzastaurin (LY317615) Before and Concomitant with Radiation Therapy, Followed by Enzastaurin Maintenance Therapy in Patients with Newly Diagnosed Glioblastoma without Methylation of the Promoter G...
    Medical condition: primary glioma without methylation of the promoter gene of MGMT enzyme
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003003-31 Sponsor Protocol Number: EORTC 26082 – 22081 Start Date*: 2009-12-01
    Sponsor Name:EORTC Headquarters
    Full Title: Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a ra...
    Medical condition: patients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoter
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006153 Brain tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002752-27 Sponsor Protocol Number: NCT-2014-0235/N2M2 Start Date*: 2018-04-04
    Sponsor Name:University Hospital Heidelberg
    Full Title: Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation: NCT Neuro Maste...
    Medical condition: Patient with newly diagnosed glioblastoma with unmethylated MGMT promoter
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001404-11 Sponsor Protocol Number: TEM-GBM_001 Start Date*: 2018-09-26
    Sponsor Name:GENENTA SCIENCE SRL
    Full Title: A phase I/IIa dose escalation study evaluating the safety and efficacy of autologous CD34+-enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the hum...
    Medical condition: Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002262-39 Sponsor Protocol Number: 131I-IPA-TLX-101-001 Start Date*: 2018-10-24
    Sponsor Name:TELIX International Pty Ltd
    Full Title: A multi-centre, open-label, single-arm, dose-finding phase I/II study to evaluate safety, tolerability, dosing schedule, and preliminary efficacy of carrier-added 4-L-[131I]iodo-phenylalanine (131I...
    Medical condition: 2nd line therapy of recurrent GBM (Glioblastoma multiforme), scheduled for repeat XRT.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) NL (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000082-38 Sponsor Protocol Number: HUM05-019 Start Date*: 2007-05-24
    Sponsor Name:Aarhus University Hospital, Denmark
    Full Title: The OPERA Study. Optimized treatment algorithm in early rheumatoid arthritis: Methotrexate and intra-articular glucocorticosteroid plus adalimumab or placebo in the treatment of early rheumatoid...
    Medical condition: In early RA methotrexate and intra-articular glucocorticoid in combination with adalimumab is better than methotrexate and intra-articular glucocorticoid in achieving control of the disease as asse...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-002417-36 Sponsor Protocol Number: CAPTEM Start Date*: 2014-08-28
    Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori
    Full Title: An open-label, randomized, multicenter, phase II trial designed to estimate the activity of CAPTEM combination versus FOLFIRI as second line treatment in patients who have progressed on or after fi...
    Medical condition: colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004865 10008442 Chemotherapies HLT
    17.0 100000004867 10069759 KRAS mutation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005437-32 Sponsor Protocol Number: ERASE-TMZ Start Date*: 2021-03-10
    Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
    Full Title: Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuva...
    Medical condition: Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10001170 Adenocarcinoma of colon stage II LLT
    21.0 100000004864 10001171 Adenocarcinoma of colon stage III LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002080-21 Sponsor Protocol Number: DETECT-01 Start Date*: 2011-07-21
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALE NIGUARDA CA' GRANDA (A.O. DI RILIEVO NAZIONALE)
    Full Title: Open-label phase 2 study of dacarbazine in patients with metastatic colorectal carcinoma based on expression of O6-methylguanine-DNA-methyltransferase (MGMT)
    Medical condition: Metastatic colorectal carcinoma (mCRC) refractory to fluoropyrimidine-, irinotecan-, oxaliplatin- (if KRAS mutated) and panitumumab- or cetuximab- (if KRAS wild type) containing regimens
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001172-21 Sponsor Protocol Number: CLO05908 Start Date*: 2015-05-18
    Sponsor Name:Genzyme Japan K.K.
    Full Title: A Phase 1, Open-label, Multi-center Study of Clofarabine in Japanese Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-002766-13 Sponsor Protocol Number: 1088/12 Start Date*: 2013-01-24
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: A phase 2 study of temozolomide in patients affected by metastatic colonrectal cancer with hypermethylation of 06-methylguanine-dna-methyltransferase
    Medical condition: metastatic colonrectal cancer
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010023 Colorectal neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002206-52 Sponsor Protocol Number: CD-ON-MEDI4736-1108 Start Date*: 2012-12-05
    Sponsor Name:MedImmune
    Full Title: A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors
    Medical condition: Advanced Solid Tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002328-10 Sponsor Protocol Number: TIGEM1-MPSVI Start Date*: 2018-10-29
    Sponsor Name:FONDAZIONE TELETHON
    Full Title: A Phase I/II Open Label, Dose Escalation, Safety Study in Subjects with Mucopolysaccharidosis type VI (MPS VI) Using Adeno-Associated Viral Vector 8 to Deliver the human ARSB gene to Liver.
    Medical condition: The clinical trial will be conducted on patients with Mucopolysaccharidosis Type VI. MPS VI is characterized by growth retardation, corneal clouding, cardiac valve disease, organomegaly, skeletal d...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006441-10 Sponsor Protocol Number: 116-02 Start Date*: 2009-06-03
    Sponsor Name:SCIPHARM SáRL
    Full Title: A double blind controlled clinical study to investigate the efficacy and tolerability of subcutaneous Treprostinil sodium in patients with severe non-operable Chronic Thromboembolic Pulmonary Hyper...
    Medical condition: Patients with Severe (inoperable) Chronic Thromboembolic Pulmonary Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) CZ (Completed) SK (Completed) DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Sep 17 16:58:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA